SmartMed Technologies calls for medical institutions to support digital health infrastructure
12/03/2019

SmartMed Technologies today announced a call for medical institutions to action towards digital health data access, endorsing global electronic health records.

Online PR News – 03-December-2019 – Yeongdeungpo-gu/SEOUL – SmartMed Technologies also called on regional health authorities, payers and procurers, and familiar medical institutions to do the same.

SmartMed Technologies also asked for more public investment in digital health blockchain infrastructures including electronic health record systems private funding for digital health blockchain companies to adhere to these standards.

SmartMed Technologies' Vice President of Research and Development, Ms. Ji-hye Yeong commented saying "With this initiative we at SmartMed Technologies contribute to a more widespread and accelerated digital health development and execution in the Asia-Pacific region and beyond. We believe patients will benefit from better networking of medical technologies through better quality of care."

"The blockchain technology of electronic health records will make it easier for people to access their health data securely across borders and medical professionals will be able to assist citizens more efficiently and effectively", added Ji-hye Yeong, Vice President of Research and Development for SmartMed Technologies.

About Us - SmartMed Technologies

SmartMed Technologies is a pioneering bioinformatics medical research and development company focused on delivering innovative medical products through artificial intelligence technology to combat prevalent, rare and emerging diseases.

Based in Seoul, our team collects and analyzes big data, utilizing artificial intelligence to gain insight into complex diseases such as leukemia and different cancers. Our approach centers on genome integration with high-performance computers and deep artificial intelligence learning.

With our advanced technology, we have been able to cut costs arising from industry trial-and-error procedures; with the integration of supercomputers into our work, we are able to run more comprehensive simulations, better target proteins, discover new drug compounds for a multitude of diseases, and generally increase our capacity for successful drug development.

With international recognition for our research and projects, some in collaboration with world-renowned institutions, we consistently aim to develop our understanding in the medical field through artificial intelligence and advanced clinical trials.